Acknowledgments Dr. Scheinman would like to acknowledge research grant support from the Deb Foundation Grant. Abbreviations: AF atrial fibrillation; AP accessory pathway; AV atrioventricular; SVT supraventricular tachycardia; WPW Wolff-Parkinson-White. http://www.selleckchem.com/products/BAY-73-4506.html Footnotes Conflict of interest: No potential conflict

of interest relevant to this article was reported.
A very troubling Inhibitors,research,lifescience,medical issue for health care systems today is that of life-sustaining selleck chem inhibitor treatment for patients who have permanently lost their cognitive capacities. These include patients in persistent vegetative state (PVS), or minimally conscious state (MCS), as well as a growing population of patients at the very end stage of dementia. These patients are totally dependent on life-sustaining treatments and are, actually, kept alive “artificially.”

Inhibitors,research,lifescience,medical This phenomenon raises doubts as to the ethics of sustaining the life of patients who have lost their consciousness and cognitive capacities, and whether there is a moral obligation to do so. The problem is that the main facts concerning the experiences and well-being of such patients and their wishes are unknown. Hence the framework of the four principles—beneficence, non-maleficence, autonomy, and justice—is not applicable in these cases; therefore we examined solidarity as another Inhibitors,research,lifescience,medical moral value to which we may resort in dealing with this dilemma. This article shows that the source of the dilemma is the social attitudes Inhibitors,research,lifescience,medical towards loss of cognitive capacities, and the perception of this state as loss of personhood. Consequently, it is suggested that the principle of solidarity—which both sets an obligation to care for the worst-off, and can be used to identify obligations that appeal to an ethos of behavior—can serve as a guiding principle

for resolving the dilemma. The value of solidarity can lead society to care for these patients and not deny them basic care and life-sustaining treatment when appropriate. Keywords: Dementia, ethics, life-sustaining treatment, Inhibitors,research,lifescience,medical minimally conscious state, persistent vegetative state, solidarity INTRODUCTION One of the very troubling issues for health care systems today is that of life-sustaining treatment for patients who have permanently lost their cognitive capacities (PLCC patients). In this paper the definition of “life-sustaining treatment” Carfilzomib is “treatment without which the patient will most likely die within six months, while he would live substantially longer with the treatment.”1 PLCC patients include patients in a persistent vegetative state (PVS), or minimally conscious state (MCS) in cases where there is no estimated chance for recovery. Also included in this category is a growing population of patients at the very end stage of dementia (as will be defined later). These conditions should not be confused with the state of brain death, which is the irreversible cessation of all function of the entire brain, including the brain-stem.